Article
Anne Chiang, MD, PhD, has been named Deputy Chief Medical Officer and Chief Integration Officer at Smilow Cancer Hospital.
Anne Chiang, MD, PhD, has been namedDeputy Chief Medical Officer and Chief Integration Officer at Smilow Cancer Hospital. Chiang will partner with Smilow Cancer Hospital leadership team to further expand multidisciplinary cancer services across the Care Center Network.
In her new role as Chief Integration Officer, Chiang will partner with the Vice President of the Smilow Cancer Hospital Network to integrate and grow oncology programs throughout the Yale New Haven Health System and with Trinity Health of New England. Dr. Chiang’s priorities include service line strategic planning, program expansion, clinical integration, volume growth, expansion of research capabilities, and facilitative leadership in the execution of the Smilow Signature of Care.
“Dr. Chiang’s impact on our Network expansion over the last decade has been immeasurable.The successful inclusion of each of the 15 Care Centers within our Network has brought Smilow cancer care into communities throughout Connecticut and Rhode Island; Dr. Chiang’s leadership has been essential to this accomplishment,” said Charles Fuchs, MD, MPH, director of Yale Cancer Center and physician-in-chief at Smilow Cancer Hospital. “Her new position will help continue to ensure Smilow quality cancer care is available to all patients throughout our Cancer Care Network.”
About Yale Cancer Center and Smilow Cancer Hospital
Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.